Publicaciones en colaboración con investigadores/as de Hospital Universitario Virgen de las Nieves (52)

2024

  1. Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study

    European urology oncology, Vol. 7, Núm. 3, pp. 447-455

  2. Real-world dosing patterns of regorafenib for patients with metastatic colorectal cancer in Spain: the RE-SEARCH study

    Clinical and Translational Oncology

  3. Real-world treatment patterns, survival outcomes, and health care resource utilization for locally advanced or metastatic urothelial carcinoma in Spain

    Clinical and Translational Oncology

  4. SEOM-GEMCAD-TTD clinical guidelines for the adjuvant treatment of colon cancer (2023)

    Clinical and Translational Oncology, Vol. 26, Núm. 11, pp. 2812-2825

  5. Sequential RAS mutations evaluation in cell-free DNA of patients with tissue RAS wild-type metastatic colorectal cancer: the PERSEIDA (Cohort 2) study

    Clinical and Translational Oncology, Vol. 26, Núm. 10, pp. 2640-2651

  6. Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer

    Clinical Cancer Research, Vol. 30, Núm. 14, pp. 3036-3049

2023

  1. Immune checkpoint inhibitor-associated thrombosis in patients with bladder and kidney cancer: a study of the Spanish Society of Medical Oncology (SEOM) thrombosis and cancer group

    Clinical and Translational Oncology, Vol. 25, Núm. 10, pp. 3021-3031

  2. Prediction of serious complications in patients with pulmonary thromboembolism and solid cancer: Validation of the EPIPHANY Index in a prospective cohort of patients from the PERSEO study

    PLoS ONE, Vol. 18, Núm. 5 May

2022

  1. Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

    European Journal of Surgical Oncology, Vol. 48, Núm. 5, pp. 1123-1132

2021

  1. Case-control analysis of the impact of anemia on quality of life in patients with cancer: A Qca study analysis

    Cancers, Vol. 13, Núm. 11

  2. Controversies in the treatment of RAS wild-type metastatic colorectal cancer

    Clinical and Translational Oncology, Vol. 23, Núm. 4, pp. 827-839

  3. Correction to: SEOM clinical guidelines for anaemia treatment in cancer patients (2020) (Clinical and Translational Oncology, (2021), 23, 5, (931-939), 10.1007/s12094-021-02580-2)

    Clinical and Translational Oncology

  4. Early clinical experience with trifluridine/tipiracil for refractory metastatic colorectal cancer: The ros study

    Cancers, Vol. 13, Núm. 18

  5. First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis

    Drugs and Aging, Vol. 38, Núm. 3, pp. 219-231

  6. Gender influence on work satisfaction and leadership for medical oncologists: a survey of the Spanish Society of Medical Oncology (SEOM)

    ESMO Open, Vol. 6, Núm. 2

  7. PD-L1 testing and clinical management of newly diagnosed metastatic non-small cell lung cancer in Spain: MOREL study

    Lung Cancer Management, Vol. 10, Núm. 4

  8. SEOM clinical guideline for management of adult medulloblastoma (2020)

    Clinical and Translational Oncology, Vol. 23, Núm. 5, pp. 940-947

  9. SEOM clinical guidelines for anaemia treatment in cancer patients (2020)

    Clinical and Translational Oncology, Vol. 23, Núm. 5, pp. 931-939

2020

  1. Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment

    Lung Cancer, Vol. 150, pp. 90-96

  2. FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: The randomised phase III VISNÚ-1 trial

    ESMO Open, Vol. 5, Núm. 6